Longevity science advances with human trials and biological breakthroughs

Longevity science has entered a transformative phase in 2026, moving from theoretical research to human clinical trials. Significant breakthroughs include the administration of the first reverse-aging drugs, which utilize epigenetic reprogramming to reset adult cells to a more youthful biological state without turning them into stem cells.

Researchers at the Hefei Institutes of Physical Science in China have discovered that the magnetotactic bacterium Magnetospirillum magneticum AMB-1 can extend the lifespan of C. elegans worms by over 43%. This effect is linked to the suppression of ferroptosis, a form of iron-dependent cell death. This discovery offers a potential new avenue for geriatric medicine.

In clinical practice, experts like Bruno Vellas, head of the HealthAge Institute in Toulouse, are advocating for a shift in medical logic. Rather than treating diseases after they appear, the focus is moving toward preserving physical and cognitive functions—such as mobility and memory—starting as early as age 50. This approach is supported by the WHO’s ICOPE program, which uses digital tools to monitor health and prevent frailty before it occurs.